Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive March 1, 2013 Sillup et al.	Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.
Pharmaceutical Executive March 1, 2009 Porth & Sillup	Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it.
Pharmaceutical Executive March 1, 2011	Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation.
Pharmaceutical Executive March 3, 2014 Sillup & Porth	Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.
Pharmaceutical Executive February 1, 2006 Porth & Sillup	Annual Press Audit: Front Page Pharma Newspapers in a study pool published more than twice as many front-page and editorial-page stories on the pharmaceutical industry than they did last year.
Pharmaceutical Executive April 1, 2007 Porth & Sillup	Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
Pharmaceutical Executive January 1, 2013 Jill Wechsler	Transformation to Characterize 2013 FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
Chemistry World December 22, 2011 Sarah Houlton	Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Pharmaceutical Executive January 1, 2007 Walter Armstrong	Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
Pharmaceutical Executive June 1, 2007 Stan Bernard	Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control.
Registered Rep. September 26, 2011 Stan Luxenberg	Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth.
Pharmaceutical Executive February 1, 2009 Jill Wechsler	Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
Pharmaceutical Executive May 1, 2011 Cacciotti & Clinton	12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies.
Pharmaceutical Executive August 1, 2008	Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how.
Pharmaceutical Executive September 1, 2012 Jill Wechsler	Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
Pharmaceutical Executive October 1, 2008 Jill Wechsler	Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans.
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
The Motley Fool September 20, 2007 Brian Orelli	Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress.
Pharmaceutical Executive June 1, 2005 Jill Wechsler	Washington Report: "D" Is for Data It is critical for Medicare to address important questions on drug safety and utilization, and about how prescribing decisions affect health outcomes and costs.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Pharmaceutical Executive February 1, 2006 Jill Wechsler	Washington Report: Cross-Agency Collaboration for Part D Medicare Part D gives CMS more clout over coverage, pricing, and even drug development.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
Reason April 2008 Ronald Bailey	Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians.
Searcher October 2010 Stephanie C. Ardito	The Medical Digital: U.S. Healthcare Reform: A Follow-Up For those interested in serious, scholarly research regarding the historical progress of U.S. healthcare reform, this column and my prior column might be a good pairing for neutral sources.
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
CFO Kris Frieswick	Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist...
Pharmaceutical Executive October 1, 2006	Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs.
The Motley Fool May 12, 2009 Brian Orelli	Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
Pharmaceutical Executive December 1, 2012 Jill Wechsler	Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	"Representing" Healthcare to the Fullest Since coming to Congress about 35 years ago, Henry Waxman, Congressional Representative from Los Angeles, California, has been pivotal in shaping legislation on health and drug regulatory issues.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	An 'A' for Advancing Expectations As head of both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, Mark McClellan has been at the center of public policy affecting the pharmaceutical industry over the last decade.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.